LAVAL, QUEBEC--(Marketwire - February 28, 2008) - Warnex Inc. (TSX: WNX) today announced that its Medical Laboratories division has obtained a licence from Xenomics, Inc. to offer NPM1 testing in Canada as a laboratory service for the diagnosis, stratification and monitoring of patients with acute myeloid leukemia (AML).
